Supernus to acquire Adamas in a deal worth up to $850 million

Oct. 11, 2021 7:04 AM ETSupernus Pharmaceuticals, Inc. (SUPN)By: Dulan Lokuwithana, SA News Editor11 Comments

The concept of the word M&A on cubes on a beautiful green background

Zhanna Hapanovich/iStock via Getty Images

  • Supernus Pharmaceuticals (NASDAQ:SUPN) has agreed to acquire Adamas Pharmaceuticals (NASDAQ:ADMS) for up to $850M worth of cash and contingent value rights. In reaction to the news, Adamas Pharmaceuticals (ADMS) has climbed ~75.1% in the pre-market.
  • Per the terms of the agreement, Supernus (SUPN) will make a tender offer of $8.10 in cash per Adamas (ADMS) share for a total value of approximately $400M.
  • The deal also includes two non-tradable contingent value rights (CVR) worth up to $1.00 per share (total value of ~$50M) for a total consideration of $9.10 per share in cash (total value of nearly $450M).
  • The CVRs, each worth $0.50 per share, are related to sales of GOCOVRI, an oral medication to treat OFF and dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy.
  • The transaction is expected to close in late Q4 2021 or early Q1 2021. The acquisition is expected to result in synergies of $60 – $80M in year one and become significantly accretive in 2022.
  • A conference call and webcast are scheduled for October 11 at 8:30 a.m. ET.
  • Supernus (SUPN) reported $855.3M in cash and equivalents as of Q2 2021 compared to $772.9M in 2020 year-end.

Recommended For You

Comments (11)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.